Background and Objective: Degenerative spine disease (DSD) imparts a substantial clinical burden as a predominant etiology for both chronic low back and neck pain. Against the backdrop of an aging population, the need for effective surgical strategies to treat DSD will rise, of which spinal fusion remains a cornerstone. Recombinant human bone morphogenetic protein-2 (rhBMP-2) has seen widespread use across spinal fusion procedures for its osteoinductive capacity, although a large percentage as off-label applications. The objective of this review is to examine current clinical evidence regarding the use of rhBMP-2 as a treatment modality for DSD alongside its adverse effects and current state of development.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: